engage:BDR generates year-on-year growth of more than 200%

Published 06-APR-2020 10:26 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

engage:BDR (ASX: EN1 and EN1O) has provided a promising trading update and commentary for its March 2020 financial performance, including a comparative analysis of the March 2019 quarter.

March 2020 revenue grew to just over $2 million, representing a 211% increase compared with March 2019.

Additionally, March results reflected an 18% month on month increase.

The strong result underpinned a robust March quarter result that featured revenue of $5.3 million, up 247% on the previous corresponding period, and representing year-on-year growth of 147%.

The following table provides a summary of the aforementioned results, but it should be noted that all figures are unaudited, as all financials are pending audit. All figures are in Australian dollars.

Anticipated second half skew in revenues

To put these results into perspective, the advertising industry traditionally expects 65-70% of its revenues in the second half of the year (July – December), as experienced by EN1 in 2019 (34%/66%).

Management expects 2020 to produce similar revenue seasonality, as experienced in 2019 and all prior years.

Due to approximately 85% of the US population currently in lockdown (stay in place orders), many brands (not specific to EN1) have temporarily reduced their marketing budgets, as consumers cannot transact with them at the moment.

As a result, the ad exchange did not see demand ramp-up as usual in the last days of the quarter.

April starts a new quarter and typically, demand is lighter in the first three weeks of the first month.

Management does not have an indication or statistically relevant data on what to expect in the June quarter, but will update shareholders consistently.

The AdCel executive team expects revenue to increase 25% in the month of April, due to new NetZero publishers going live and maintaining consistent, uninterrupted international demand.

New financing opportunities

In light of significant interest rate reductions, EN1’s 2019 audited financial results and the US government’s US$2.2 trillion stimulus program, management has applied for several new financing opportunities, none of which involve equity.

Management is currently working with a large tier-1 Australian bank in the application process (3 to 4% APR).

Additionally, EN1 qualifies and has applied for US SBA loans under the CARES Act, with UMB Bank US (2 to 3%).



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X